Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281301 | 0.92 | KMT2A (0.56) | MEN1KMT2AF2MAPTLMNA | |
| SCHEMBL6282573 | 0.90 | MEN1 (0.51) | MEN1KMT2AF2MAPTLMNA | |
| SCHEMBL6277614 | 0.88 | KCNH2 (0.54) | MEN1KMT2AMAPTKCNH2 | |
| SCHEMBL6285051 | 0.88 | ALDH1A1 (0.47) | MEN1KMT2ALMNA | |
| SCHEMBL6283579 | 0.86 | KCNH2 (0.62) | MEN1KMT2AF2MAPTKCNH2 | |
| SCHEMBL6362883 | 0.82 | KCNH2 (0.59) | KCNH2 | |
| SCHEMBL6281656 | 0.80 | LMNA (0.50) | MEN1KMT2AMAPTLMNA | |
| SCHEMBL6278038 | 0.80 | KCNH2 (0.45) | MEN1KMT2AF2MAPTKCNH2 | |
| SCHEMBL6283822 | 0.80 | — | — | |
| SCHEMBL6277664 | 0.80 | KCNH2 (0.54) | MEN1KMT2AMAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | claimed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | MEN1 2456/4885KMT2A 731/4885F2 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.